A Randomized, Blinded Placebo-Controlled Study to Evaluate the Effect of Repeat Oral Doses of Pazopanib (GW786034) on the Electrocardiogram (ECG) With Focus on Cardiac Repolarization (QTc Duration) in Subjects With Solid Tumors

Trial Profile

A Randomized, Blinded Placebo-Controlled Study to Evaluate the Effect of Repeat Oral Doses of Pazopanib (GW786034) on the Electrocardiogram (ECG) With Focus on Cardiac Repolarization (QTc Duration) in Subjects With Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Moxifloxacin; Pazopanib
  • Indications Bacterial infections; Solid tumours
  • Focus Pharmacodynamics
  • Most Recent Events

    • 06 Apr 2010 Actual patient number (96) added, actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
    • 06 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Aug 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top